

West Virginia Medicaid Drug Utilization Review Board Minutes May 22, 2024

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Ernest Miller, DO

Members Absent:

Mary Nemeth-Pyles, MSN, RN, CS

DHHR/BMS Staff:

Priya Shah, PharmD, Drug Utilization Review Coordinator
Vicki Cunningham, PharmD, Director of Pharmacy
Hyla Harvey, MD, WV Medicaid Medical Director
Kristen Boustany, PharmD
Gail Goodnight, PharmD
William Hopkins, PharmD, Pharmacy Operations Manager
Lori Moles, PharmD
Doug Sorvig, Data Analyst

Contract Staff:

Joe Bergondo, PharmD – Change Healthcare
Jacquelyn Hedlund, MD – Change Healthcare
Eric Sears, RPh – Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Alena Mitchell, PharmD – Acentra Health

1. **INTRODUCTIONS**
 - a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:02 PM (EST). The DUR Board and others introduced themselves.
2. **APPROVAL OF MINUTES FROM February 14th, 2024 DUR BOARD MEETING**
 - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.
3. **OLD BUSINESS**
 - a. None
4. **NEW BUSINESS**
 - a. **Speakers**
 - i. None
 - b. **Updates from April 2024 P&T Committee Meeting**
 - i. April 2024 P&T Committee Meeting was canceled. No updates.
 - c. **Prior Authorization Criteria.** Attachment A
 - i. **Spravato:** approved as amended.
 1. Additional definition of non-compliance with reference to oral antidepressants.
 2. Non-compliance is defined as filling >10 days past fill date.
 - ii. **Tryvio:** approved as amended.
 1. Removal of potassium-sparing diuretics from required trial/failure list.
 2. Addition of mineralocorticoid diuretics to list of drug classes on criteria #5.
 - iii. **Hepatitis C Patient-Provider Agreement:** approved as amended.
 1. Objection from manufacturer acknowledged.
 2. Dr. Harvey recommended future edits to emphasize risks of reinfection and hepatic damage.
 - iv. **Albenza and Emverm:** approved as presented.
5. **REPORTS – 1st Quarter of 2024**
 - a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2024 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the First Quarter of 2024. Attachment C.
 - c. **Acentra Health:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the First Quarter of 2024. Attachment D.
6. **OTHER BUSINESS**
 - a. Dr. Babcock
 - i. No preferred injectable glucagon pen since the previously preferred product was discontinued and other products are on shortage.
 1. Vicki Cunningham responded that the PA requirement was removed from Baqsimi, and that Zegalogue is also available without a PA. Other pens are unavailable.

ii. Fluticasone MDI generic product is not on formulary, even though Flovent HFA is now discontinued.

1. Vicki Cunningham responded that generic is expensive but that fluticasone MDI can be approved, if other ICS have been tried/failed.

7. **NEXT MEETING AND ADJOURNMENT**

a. The meeting concluded at 5:34 PM (EST).